You are here: All Products  > 280Bio, a Yingli Pharma Subsidiary, to Start US Trials of RAS Inhibitor

280Bio, a Yingli Pharma Subsidiary, to Start US Trials of RAS Inhibitor

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products